Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A regimen for low-dose aspirin?

S P Hanley, J Bevan, S R Cockbill

    British Medical Journal (Clinical Research Ed.)
    |November 6, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Clearing the air: Assessing healthcare professionals' awareness of air pollution's health consequences.

    Future healthcare journal·2024
    Same author

    A Remote Assay for Measuring Canine Platelet Activation and the Inhibitory Effects of Antiplatelet Agents.

    Journal of veterinary internal medicine·2017
    Same author

    Sagit©: A Novel Clinician-Reported Outcome for Managing Acromegaly in Clinical Practice.

    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
    Same author

    Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders.

    Journal of thrombosis and haemostasis : JTH·2014
    Same author

    'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.

    Thrombosis and haemostasis·2013
    Same author

    Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.

    Platelets·2012

    Aspirin 40 mg every 48 hours effectively inhibits platelet aggregation by reducing thromboxane A2 synthesis. This regimen may offer the maximum antithrombotic effect compared to less frequent dosing.

    Area of Science:

    • Cardiovascular Pharmacology
    • Thrombosis Research
    • Antiplatelet Therapy

    Background:

    • Platelet aggregation and vascular prostacyclin synthesis play crucial roles in thrombosis.
    • Understanding the optimal aspirin dosage for balancing these effects is clinically significant.

    Purpose of the Study:

    • To evaluate the impact of different 40 mg aspirin regimens on platelet thromboxane A2 and vascular prostacyclin synthesis.
    • To determine the optimal dosing interval for aspirin's antithrombotic potential.

    Main Methods:

    • Patients undergoing elective varicose vein surgery were administered 40 mg aspirin at 48-hour or 72-hour intervals.
    • Platelet thromboxane A2 and vascular prostacyclin synthesis were measured at various time points post-administration.

    Related Experiment Videos

    Main Results:

    • Aspirin 40 mg every 48 hours consistently suppressed platelet thromboxane A2 synthesis, inhibiting platelet aggregation for at least 36 hours.
    • Aspirin 40 mg every 72 hours showed less consistent effects on thromboxane A2.
    • Both regimens caused transient, short-lived reductions in vascular prostacyclin synthesis.

    Conclusions:

    • The 48-hour aspirin regimen demonstrates superior and sustained inhibition of platelet thromboxane A2 synthesis.
    • 40 mg aspirin every 48 hours may provide the maximal antithrombotic effect by optimizing the balance between thromboxane A2 and prostacyclin synthesis.